BeOne Medicines Ltd. / Huahui Health Ltd.

Solid Tumors (PD-1/CTLA-4/VEGF Trispecific Oncology)

1.9M US cases/yr · $50.0B US Market · 0.51 Ivonescimab HARMONi-2 PFS HR vs pembrolizumab

Disease Overview

Solid tumor immuno-oncology has been transformed by checkpoint inhibitors targeting PD-1 (e.g., pembrolizumab, nivolumab) and CTLA-4 (ipilimumab), but durable responses remain limited to a minority of patients across most indications. Combination regimens that pair PD-1 blockade with anti-CTLA-4 or anti-angiogenic agents have demonstrated additive efficacy but at meaningful safety cost, particularly immune-related adverse events from CTLA-4 plus PD-1 doublets. The emergence of bispecific PD-1 x VEGF antibodies, led by Akeso/Summit's ivonescimab (AK112) which secured Chinese marketing approval in 2024 and demonstrated superiority over pembrolizumab in HARMONi-2 NSCLC, has reset competitive expectations for first-line lung and other epithelial cancers. Trispecific antibodies that simultaneously engage PD-1, CTLA-4, and VEGF-A represent the next architectural step, theoretically combining checkpoint reactivation, immune amplification, and tumor microenvironment normalization in a single molecule with controlled stoichiometry. The 7MM oncology immunotherapy market exceeds $50 billion annually and is projected to expand to over $100 billion by 2030, with PD-(L)1 combination regimens commanding the largest growth share. Trispecific architectures aim to capture the safety and convenience advantages of single-molecule administration while delivering combination-level efficacy across NSCLC, gastric, hepatocellular, biliary tract, and gynecologic cancers.

Competitive Landscape

The PD-1/VEGF combination space is led commercially by Akeso/Summit's ivonescimab, the first PD-1xVEGF bispecific to win marketing approval (China) and currently in pivotal global Phase 3 NSCLC, biliary tract, and head & neck programs. Trispecific antibodies adding CTLA-4 to the PD-1/VEGF backbone include CStone's CS2009, which received FDA Phase II clearance in February 2026, and Hengrui's HC010, both currently behind HH160 in clinical staging. HH160 is preclinical with the only public scientific disclosure being a 2025 AACR poster, leaving CMC scalability, exposure-response, and tumor-type entry strategy as critical open questions. BeOne's $20M upfront plus $100M option-exercise structure preserves optionality while gating commitment on additional preclinical/early-clinical de-risking. Strategic logic: low near-term capital, high upside if HH160 differentiates on safety versus checkpoint+anti-VEGF combinations, and BeOne's existing PD-1 (tislelizumab/Tevimbra) infrastructure positions it to integrate the trispecific into combination regimens or as a single-agent successor.